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ABSTRACT
The resurgence of pertussis infection worldwide, including Malaysia, is alarming. Young children have the highest 
reported pertussis incidence and death rates. However, little is known of the risk factors of pertussis in Malaysia. In this 
study, we aimed to determine the risk factors of pertussis infection among children. We conducted a case-control study 
involving 143 children aged ≤2 years from Selangor, Malaysia. The children were identified from eNotifikasi, a web-
based notification site, from 1 January to 31 December, 2018. Information on clinical presentation and risk factors 
were collected during investigation of the case by the district health office. Multivariate analysis showed that the odds 
for pertussis were higher among children aged <3 months (adjusted odds ratio (aOR) 5.54; 95% confidence interval 
(CI); 1.835, 16.710) and among children who had not received their vaccination according to age (aOR 5.641; 95% CI; 
1.845, 17.245). The mean duration of cough among the cases was 10.22 days (SD 8.964); that of the controls was 6.47 
days (SD 7.098). Paroxysmal cough (93.6%) was the predominant symptom among the cases. A total of 42.6% of 
cases were aged <2 months, whilst most of the controls were aged >5 months (40.4%). Up to 42.6% of cases and 68.7% 
of controls were immunised according to their age. Therefore, it is important to ensure that children are vaccinated 
once they have attained the appropriate age.
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ABSTRAK
Kemunculan semula jangkitan pertusis atau batuk kokol di seluruh dunia, termasuk Malaysia, adalah membimbangkan. 
Kanak-kanak merupakan kumpulan dengan kadar insiden dan kematian tertinggi direkodkan. Walau bagaimanapun, 
maklumat risiko jangkitan tersebut amat sedikit di Malaysia. Oleh itu, kajian ini dijalankan bagi menentukan faktor 
risiko jangkitan pertusis dalam kalangan kanak-kanak. Kajian kes kawalan dijalankan melibatkan 143 kanak-kanak 
berusia ≤2 tahun. Subjek dikenal pasti melalui sistem eNotifikasi dari 1 Januari sehingga 31 Disember, 2018. Maklumat 
berkaitan dengan tanda-tanda klinikal dan faktor risiko diperoleh semasa siasatan kes oleh pejabat kesihatan daerah. 
Analisis multivariat mendapati bahawa risiko penjangkitan pertusis adalah tinggi pada bayi berusia <3 bulan (aOR 
5.54; 95% CI; 1.835,16.710) dan kanak-kanak yang tidak menerima vaksinasi seperti dijadualkan (aOR 5.641; 95% 
CI; 1.845,17.245). Purata jangka masa batuk dalam kalangan kes adalah 10.22 hari (SD 8.964); purata jangka masa 
batuk dalam kalangan kawalan adalah 6.47 hari (SD 7.098). Batuk paroksisma (93.6%) merupakan gejala utama pada 
kes. Sejumlah 42.6% kes berusia <2 bulan, manakala majoriti kumpulan kawalan berusia >5 bulan (40.4%). Sebanyak 
42.6% kes dan 68.7% kawalan telah diberi vaksin mengikut jadual. Kesimpulannya, adalah penting bagi kanak-kanak 
diimunisasi mengikut jadual yang telah ditetapkan.
Kata kunci: DtaP; faktor; imunisasi; kanak-kanak; pertusis
INTRODUCTION
Children and young infants, especially those aged ≤2 
years, are vulnerable to infectious disease (Edwards 
2014; Esposito & Principi 2016). Many countries have 
introduced immunisation schedules for children as a 
preventive method against vaccine-preventable diseases 
(VPD) (WHO 2018a, 2015). Pertussis is a VPD and is an 
acute infection caused by the Gram-negative bacteria 
(WHO 2017a) Bordetella pertussis, which is transmitted 
person-to-person through direct contact with the airway 
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secretions of an infected person or indirectly by touching 
a contaminated surface (WHO 2017a). To date, humans are 
the only known reservoir for B. pertussis (Tiwari 2005). 
However, a recent study in naïve baboons noted that the 
species can be infected with B. pertussis (Warfel et al. 
2016), and entirely airborne transmission of the bacteria 
can occur (Warfel et al. 2012). Pertussis tends to occur 
in younger infants and cause a severe life-threatening 
condition (Edwards 2014; Esposito & Principi 2016).
In 2014, there were an estimated 24.1 million cases 
globally in children aged <5 years, including 5.1 million 
cases among infants (WHO 2018a; Yeung et al. 2017). 
The incidence rate of pertussis in Malaysia also shows 
an increasing trend, from 0.2/100,000 population to 
1.0/100,000 population, over the past twenty years (MOH 
2017). However, it is believed that the true incidence 
of pertussis is notably higher than the data captured 
by reporting and surveillance systems due to incorrect 
diagnosis, under-reporting and low consultation, especially 
among adolescents and adults with mild symptoms 
(Esposito & Principi 2016). In Malaysia, pertussis is a 
mandatory notifiable disease and is monitored under a 
surveillance system (WHO 2018b). Besides, the increasing 
prevalence of pertussis infection increases the healthcare 
burden (Koh et al. 2016; Van Hoek et al. 2014). For 
pertussis cases, the estimated overall loss of quality of 
life is 0.097 quality-adjusted life years (QALYs) (Van 
Hoek et al. 2014). In 2012, the medical-related cost in 
Malaysia was around 2% of the average monthly wage 
(Koh et al. 2016).
Multiple international studies have shown a number 
of risk factors linked to pertussis infection, such as 
waning immunity against pertussis in the community 
(Cherry 2012), infection transmission from asymptomatic 
individuals (Althouse & Scarpino 2015) and vaccine 
refusal or delay (Glanz et al. 2013). However, research 
on this issue in Malaysia is very scarce. Furthermore, 
the increasing trend of the anti-vaccine movement adds 
to the underlying problem of vaccine defaulters, thus 
contributing to the resurgence of pertussis. Unpublished 
data by the Ministry of Health Malaysia (MOH) shows 
that the number of vaccine refusal cases increased from 
600 in 2013 to 1600 in 2016 (Faridah 2017). Although 
the vaccination rate in Malaysia has always been high 
(WHO 2018a; 2018b), there remain pockets of vaccine 
refusal in many communities. This poses a threat to the 
local population, as the risk for VPD outbreak, including 
pertussis is high (Phadke et al. 2016; Smith 2017). Thus, 
the main aim of the present study was to determine 
the risk factors associated with pertussis infection 
among children in Selangor and to describe the clinical 
presentation of the cases.
MATERIALS AND METHODS
STUDY SETTING
According to Malaysia’ Act 342 (LOM 2006), all 
suspected pertussis cases must be notified to the nearest 
district health office. All notified cases are captured in 
the real-time, web-based notification system, eNotifikasi. 
Any suspected case with suggestive clinical features of 
pertussis infection diagnosed by health facilities must 
be notified to the nearest district health office (DHO). A 
confirmatory laboratory test, either by PCR or culture, 
must proceed together with the notification. A positive 
test is classified as a confirmed case. In Malaysia, PCR 
is mainly used for laboratory confirmation of pertussis, 
as it yields results quickly (DCD 2010). Subsequently, 
the DHO investigates each notified case using a Pertussis 
Investigation Form. Here, we conducted a case–control 
study using the data captured in the form in Selangor, 
Malaysia from 1 January, 2018 to 31 December, 2018.
SAMPLE SIZE
The minimum sample size calculated using PS: Power 
and Sample Size Calculation (Dupont & Plummer 2009) 
based on multiple risk factors (Curtis et al. 2017; Deeks et 
al. 1999; Glanz et al. 2013), with a confidence interval (CI) 
of 95% and power of 80%, was 150 (50 cases and 100 
controls), allowing for a 20% missing data rate.
SAMPLE SELECTION
Stratified random sampling was performed (Figure 1). 
Initially, a list of positive and negative cases was obtained 
from the eNotifikasi system. Both lists were stratified 
into all nine districts in Selangor based on the addresses. 
Then, a proportion of positive cases was selected from 
each district based on the total number of cases required 
using the simple random technique by SPSS software 
(IBM 2013). Cases were defined as children aged ≤2 years 
with laboratory-confirmed pertussis. For every case, we 
included two controls from the same district. Controls 
were captured from the list of discarded (negative) 
cases using the simple random technique. Children were 
excluded if the DHO had been unable to investigate them 
and if the child had died during the investigation. The 
same applied to the control, with the additional exclusion 
criterion of no sample obtained.
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INSTRUMENTS
The form includes demographic data, signs and symptoms, 
complications, immunisation status, breastfeeding 
status, suspected sources of infection, and laboratory 
results. Information on clinical signs and symptoms 
and complications related to pertussis was obtained for 
both groups. The risk covariates were divided into two 
groups: The individual’s covariates: age (0-1 months, 2 
months, 3-4 months, ≥5 months), sex (male/female), race 
(Malay/Chinese/Indian/Other), immunisation status (age-
appropriate immunisation: dose 1 at 2 months, dose 2 at 
3 months, dose 3 at 5 months, booster dose at 18 months; 
those with age-appropriate immunisation were classified 
as yes; those aged <2 months were classified as unqualified 
for immunisation) and number of doses (0/1/2/3/4), 
breastfeeding status (breastfeeding/mixed feeding/
formula milk feeding); Their contacts’ covariates: Source 
of infection (household/other/unknown) and symptom 
status (symptomatic/asymptomatic). In Malaysia, pertussis 
immunisation is administered through the Diphtheria-
Tetanus-acellular Pertussis (DTaP) vaccine, with primary 
doses given at 2, 3 and 5 months, and a booster dose at 
18 months. The presence of any type of complication was 
classified as yes.
STATISTICAL ANALYSIS
All data collected and extracted were analysed using 
the software Statistical Package for the Social Sciences 
version 22 (SPSS 22) (IBM 2013). Categorical data 
are expressed as frequencies (n) and percentage (%); 
continuous data are expressed as the mean and standard 
deviation (SD). Bivariable comparison of risk factors 
between the cases and controls was calculated using 
simple logistic regression; the multivariable test using 
stepwise logistic regression was performed to assess the 
impact of several factors on the likelihood of pertussis 
infection and for obtaining important risk factors 
of pertussis infection. The odds ratio (OR) for each 
independent variable in the model was estimated 
using a logistic regression coefficient. A p-value < 0.05 
was used as the level of significance. Interaction and 
multicollinearity were checked.
ETHICAL APPROVAL
This research was approved by the National Medical 
Research Registry of Malaysia (NMRR ID: NMRR-19-
534-46053) and the Research Ethics Committee (REC) of 
Universiti Kebangsaan Malaysia (Ref no.: UKM PPI.800-
1/1/5/JEP-2019-405).
RESULTS
Out of 1085 notifications, a total of 256 laboratory-
confirmed cases were recorded in Selangor from 1 
January, 2018, until 31 December, 2018, of which 253 
cases (98.8%) were children. Of these, 241 (95%) were ≤2 
years old. A final 146 children were enrolled in the study: 
FIGURE 1. The sampling protocol for the study
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47 pertussis cases and 97 negative controls. The mean age 
of the cases was 3.9 months (SD 4.4) months; 51.1% were 
female (Table 1). The majority of cases were Malaysian 
citizens (97.9%) and were Malay (91.5%). Only 42.6% 
of cases had received immunisation according to age; 
68.7% of the control group had been immunised up-to-
age. Around 55.3% of the cases had never have received 
any DTaP vaccine previously; in contrast, the control 
group had a lower portion of unimmunised children, i.e. 
29.3%. Regarding the source of infection, 51.1% of the 
cases and 53.5% of the controls were unsure of the 
suspected source, with no or unknown contact with an ill 
person. Most of the children were born at term and were 
breastfed solely or were on mixed feeding. Regarding 
clinical presentation, the mean days of cough before 
cases received treatment was 10.2 days; only 30% of 
cases had a history of prolonged cough for >14 days. The 
top three common symptoms the cases experienced were 
paroxysmal cough (93.6%), fever (57.4%) and post-tussive 
vomiting (51.1%); the most common complication was 
pneumonia (21.3%) (Figures 2 & 3).
TABLE 1. Descriptive analysis showing the characteristics of the children
Case n (%) Total
Control
Socio-demographics
Citizenship Malaysian 46 (97.9) 97 (98.0) 143 (97.9)
Non-Malaysian 1 (2.1) 2 (2.0) 3 (2.1)




0–1 9 (19.1) 15 (15.2) 24 (16.4)
2 20 (42.6) 18 (18.2) 38 (26.0)
3–4 7 (14.9) 26 (26.3) 33 (22.6)
≥5 11 (23.4) 40 (40.4) 51 (34.9)
Race Malay 43 (91.5) 93 (93.9) 136 (93.2)
Chinese 1 (2.1) 0 (0) 1 (0.7)
Indian 2 (4.3) 2 (2) 4 (2.7)
Other 1 (2.1) 4 (4) 5 (3.4)
Sex Male 23 (48.9) 56 (56.6) 79 (54.1)
Female 24 (51.1) 43 (43.4) 67 (45.9)
Clinical presentation: Days of cough before seeking 
treatment, mean (SD)
10.22 (8.96) 6.97 (7.10)




Yes 20 (42.6) 68 (68.7) 88 (60.3)
Unqualified 15 (31.9) 23 (23.2) 38 (26.0)
No 12 (25.5) 8 (8.1) 20 (13.7)
DTaP dose 1 12 (25.5) 16 (16.2) 28 (19.2)
2 3 (6.4) 22 (22.2) 25 (17.1)
3 6 (12.8) 31 (31.3) 37 (25.3)
4 0 1 (1) 1 (0.7)
0 26 (55.3) 29 (29.3) 55 (37.7)
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Source and contact
Suspected source of 
infection
Household 20 (42.6) 29 (29.3) 49 (33.6)
Unknown 24 (51.1) 53 (53.5) 77 (52.7)
Other 3 (6.4) 17 (17.2) 20 (13.7)
Contact health status Symptomatic (Yes) 19 (40.4) 36 (36.4) 55 (37.7)




Household 16 (34) 25 (25.3) 41 (28.1)
Other 5 (10.6) 14 (14.1) 19 (13.0)
Not relevant 26 (55.3) 60 (60.6) 86 (58.9)
Birth and feeding
Gestation Term 40 (85.1) 84 (84.8) 124 (84.9)
Preterm 7 (14.9) 15 (15.2) 22 (15.1)
Feeding status Breastfeeding only 24 (51.1) 38 (38.4) 62 (42.5)
Formula milk 3 (6.4) 19 (19.2) 22 (15.1)
Mixed feeding 20 (42.6) 42 (42.4) 62 (15.1)
FIGURE 2. The distribution of clinical presentation among the cases and controls



































































































Distribution of complications among cases and controls, n = 47
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In the bivariable analysis, only the risk factors were 
analysed. We did not analyse the clinical presentation 
and complications further. The analysis showed three 
significant factors: Age group, immunisation status and 
DTaP vaccine dosage received (Table 2). Infants aged 
2 months had 4.04 greater odds of being infected 
compared to those aged ≥3 months (p = 0.003). Children 
who had not been immunised according to their age were 
5.1 more likely to develop pertussis than those who had 
been immunised accordingly (p = 0.002). Children who 
had received two (p = 0.019) and three doses (p = 0.021) 
were 1.5-2 times less likely to be infected compared to 
those who did not receive any vaccination. The more 
DTaP dosages received, the less likely the child would 
be infected.
TABLE 2. Association of risk factors with pertussis infection
Variables Crude OR 95% CI χ2 (df)a p-valuea
Citizenship Malaysian 0.95 0.08, 10.73 0.01 (1) 0.966
Non-Malaysian 1.00
Race Malay 0.69 0.19, 2.59 0.29 (1) 0.590
Non-Malay 1.00
Sex Male 0.74 0.37, 1.48 0.75 (1) 0.388
Female 1.00
Age, months 11.85 (3) 0.008
0–1 2.18 0.75, 6.31 2.07 (1)b 0.150b
2 4.04 1.61, 10.16 8.80 (1)b 0.003b
3–4 0.98 0.34, 2.85 0.002 (1)b 0.969b
≥5 1.00






Unqualified 2.22 0.98, 5.03 3.63 (1)b 0.057b
No 5.10 1.83, 14.20 9.72 (1)b 0.002b
DTaP dose 17.99 (4) 0.001
1 0.84 0.33, 2.09 0.15 (1)b 0.70b
2 0.15 0.04, 0.57 7.85 (1)b 0.019b
3 0.22 0.08, 0.60 8.65 (1)b 0.021b
4 <0.01 <0.01 <0.01 (1)b 1.000b
0 1.00
Suspected source of 
infection
4.74 (2) 0.093
Household 3.91 1.01, 15.12 3.90 (1)b 0.048b
Unknown 2.57 0.69, 9.59 1.96 (1)b 0.161b
Other 1.00
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Contacts’ health status 
(Symptomatic)






Household 1.48 0.68, 3.22 0.97 (1)b 0.33b
Other 0.82 0.27, 2.53 0.12 (1)b 0.735b
Not relevant 1.00
Gestation Term 1.00
Preterm 1.02 0.39, 2.70 0.01 (1) 0.968
Feeding status 5.21 (2) 0.074
Breastfeeding 1.00
Formula milk 0.25 0.07, 0.94 4.23 (1)b 0.040b
Mixed feeding 0.75 0.36, 1.58 0.56 (1)b 0.453b
aLikelihood ratio test, bWald test, df, Degree of freedom
Multivariable analysis was performed using all 
variables that were significant in the bivariable analysis. 
The final backward stepwise model containing both 
predictors was statistically significant (χ2 (6, n = 146) 
= 22.013, p = 0.001). The model correctly classified 
71.2% of cases. Neither interaction nor collinearity was 
present. Infants aged <3 months had 5.5 times greater 
odds of being infected compared to those aged ≥5 
months. Meanwhile, children who had never received 
any vaccination against pertussis had 5.6 times higher 
odds of infection than those who had been immunised 
according to schedule (Table 3).






Age, months 0–1 2.18 4.04 (0.72, 22.64) 2.51 (1)b 0.113b
2 4.04 5.54 (1.84, 16.71) 9.23 (1)b 0.002b





Unqualified 2.217 0.90 (0.23; 3.45) 0.03 (1)b 0.873b
No 5.10 5.64 (1.845, 17.245) 9.208 (1)b 0.002b
aLikelihood ratio test, bWald test, df, Degree of freedom
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DISCUSSION
Our results indicate that young infants are vulnerable to 
pertussis infection. This finding is consistent with that of 
other studies (Masseria et al. 2017; Winter et al. 2015). 
Another study in Malaysia reported similar findings, where 
the majority of positive PCR results were from children 
aged <3 months (Ting et al. 2013). Due to the immunisation 
schedule, there is a window of vulnerability for pertussis 
infection in infants aged <2 months. Younger infants are 
more vulnerable to infection because their immunity has 
not fully matured. Besides, immunity against infection is 
not long-lasting, even in people who have previously been 
infected or immunized, thus rendering young infants 
more vulnerable (Cherry 2016). If a deduction were to 
be made based on age group, it would be that the first 
dose of DTaP does not confer protection against pertussis 
infection, while the second and third doses do, as shown 
in the bivariate analysis. Radke et al. (2017) reported a 
similar finding, where vaccine effectiveness increased with 
the number of doses received, at least until the primary dose 
had been completed. However, we observed that although 
the children might not have received a complete primary 
dose of DTaP vaccine, receiving vaccination according 
to their age means that the children would be protected 
compared to children who have missed their vaccination. 
This is supported by Glanz et al. (2013), McNamara et 
al. (2017) and Radke et al. (2017). 
The effectiveness of the acellular pertussis vaccine 
in protecting children according to the number of doses 
received has been demonstrated (Radke et al. 2017). 
However, no formal efficacy study has addressed the 
effect of incomplete primary dose or a single dose (WHO 
2017a). The difference recorded in the present study was 
because 39.7% of the children had not received their 
immunization, although one-third of them had attained 
the appropriate age for vaccination. There might be similar 
findings in other states in Malaysia, especially those with 
similar demographic and socioeconomic distribution 
to Selangor. Through the Malaysia National Health and 
Morbidity Survey 2016, Lim et al. (2017) noted that the 
vaccination coverage of DTaP among participants aged 
0-59 months was 89.0-89.8% for the three doses. 
In the present study, we found a higher rate of 18.5% 
non-vaccinated children among those who qualified 
for the vaccine. Although the rate appears sufficient 
for herd immunity level, we should bear in mind that 
immunity against pertussis is not long-lasting. Hence, 
this will increase the pool of non-immune people over 
time. In comparison with regional and global vaccination 
coverage, which is 85-94% for DTaP1 and DTaP3 (WHO 
2019a, 2019b, 2018c), our findings indicate slightly lower 
coverage in Malaysia. The MOH has made continual efforts 
to ensure high vaccine coverage, such as the National 
Immunisation Campaign, the provision of immunisation 
kits to clinics as education material, training healthcare 
workers as vaccine advocates, forums and seminars with 
multiagency collaboration, and promotion through social 
media and mass media (Faridah 2017).
Multiple studies have shown that adult and maternal 
vaccination of Tdap (Tetanus, diphtheria, acellular 
pertussis) given during pregnancy is effective for 
preventing pertussis in new-borns, at least until the child 
has received their vaccination (Curtis et al. 2017; Forsyth 
et al. 2015), as breastfeeding does not confer protection 
against pertussis (Pandolfi et al. 2017). Besides that, 
a few studies have shown the role of households or 
mothers as a risk factor for infection (Hughes et al. 2017; 
Winter & Harriman 2018). The Advisory Committee 
on Immunisation Practices (ACIP) recommends a 
Tdap booster for adults with no previous immunization 
and a dose of Tdap at 27-36 weeks of gestation during 
each pregnancy for women regardless of the previous 
vaccination (Liang et al. 2018). Nevertheless, we found 
that contact status and relationship were not significant. 
However, there might be a role for introducing adult or 
maternal Tdap vaccination to curb pertussis among young 
infants in Malaysia, as there is evidence of elevated risk of 
pertussis among younger infants. Tdap vaccination would 
increase the population’s herd immunity and protect 
younger infants from contracting the infection.
Here, the mean duration of cough among the cases 
was shorter than the conventional clinical criteria for 
pertussis, which is 14 days (CDC 2014; WHO 2017b). 
However, in recent years, international organizations 
have made an exception for prolonged cough as the 
clinical criteria, especially among children aged <1 year. 
The Centers for Disease Control and Prevention (CDC) 
has stated that the presence of apnoea (with or without 
cyanosis) in infants, paroxysmal cough, inspiratory whoop 
or post-tussive vomiting with cough of any duration 
are clinical criteria for pertussis (CDC 2014). A study 
conducted among infants with critical pertussis in a tertiary 
healthcare centre in Malaysia noted a mean duration of 
cough of 1 week (Lin et al. 2016). Meanwhile, a study 
in North-West Malaysia found that cyanosis was the 
only symptom associated with pertussis (Salwana et al. 
2017), a similar finding to ours. In contrast, a systematic 
review by Ebell et al. (2017) noted greater susceptibility to 
whooping cough (41%) and post-tussive vomiting (56%), 
whilst children were four times more likely than adults 
to present with whooping cough. However, the overall 
presentation is the most accurate predictor, rather than 
individual signs or symptoms (Moore et al. 2017). The 
authors also noted that vaccinated children tend to lack 
the typical signs and symptoms of pertussis, explaining 
the low rate of clinical suspicion among them compared to 
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unvaccinated children. A meta-analysis noted that apnoea 
and cyanosis were both moderately specific and sensitive 
in infants, while post-tussive vomiting was less helpful as a 
clinical diagnostic criterion (Moore et al. 2017). Regarding 
complications, most of the cases developed pneumonia. 
A study in Peru has reported similar findings (Del Valle-
Mendoza et al. 2018).
LIMITATIONS AND STRENGTHS
In the present study, the control group comprised those 
initially suspected as pertussis. Therefore, clinical signs 
and symptoms were likely to be similar to that in the 
cases. However, the CDC (2017) has stated there is 
an increased likelihood of false positive results if an 
asymptomatic person is tested with PCR, as PCR can 
detect more cases than culture (Ting et al. 2013). The 
sensitivity of PCR is 70-99%, with 86-100% specificity 
(APHL & CDC 2010). Several potential confounding 
factors that may be associated with vaccination status 
and exposure to pertussis were not included in the study, 
as the investigation form does not routinely capture such 
information; examples include coverage of immunity and 
geography (Curtis et al. 2017; Esposito & Principi 2016; 
Levri et al. 2016). However, we were able to match the 
geographical locations of the cases and controls in the 
district, which helped to control the factors. Nonetheless, 
our findings may contribute to explaining the increasing 
trend of pertussis cases, especially among infants. The 
study design yielded better strength of association 
between the risk factors and pertussis infection in the 
population as compared to a cross-sectional study, and the 
sampling method ensured that there were representatives 
for each district in Selangor.
CONCLUSION
Our study shows that pertussis infection is associated 
with younger infants, especially those aged <3 months, 
and the role of complying with the vaccination schedule 
accordingly. Therefore, it is recommended all health 
facilities ensure that all children are vaccinated 
according to the national vaccination schedule to ensure 
that each locality achieves herd immunity. In addition, 
a strengthened government policy on immunisation 
schedule, such as compulsory childhood vaccination, 
should be established.
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